Montpellier

• Nivolumab and ipilimumab in patients with dMMR and/or MSI metastatic colorectal cancer resistant to anti-PD1 monotherapy: An open-label phas … Ended recruitment
  2024-516313-20-00 4 2022-04-19 Metastatic colorectal cancer
• A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can … Ended recruitment
  2023-503826-37-00 5 2022-02-11 Unresectable locally-advanced or metastatic HER2+ breast cancer
• A study to learn how well finerenone works; how safe it is; how it moves into, through, and out of the body; and the effects it has on the b … Ended recruitment
  2023-504884-17-00 5 2022-02-04 Proteinuria
• OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated ma … Ended recruitment
  2024-512634-15-00 9 2022-01-05 Patients with untreated mantle cell lymphoma
• Multi-drug treatment for breast cancer patients with brain metastases Ended recruitment
  2024-510703-11-00 4 2021-12-13 HER2+ metastatic breast cancer with isolated brain progression
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in … Ended recruitment
  2023-506518-33-00 5 2021-11-10 Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• Efficacy of Abatacept vs Adalimumab in Early, Autoantibody positive Rheumatoid Arthritis (RA) and who did not respond well to methotrexate. Ended recruitment
  2023-506450-20-00 5 2021-11-05 Rheumatoid Arthritis
• Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati … Ended recruitment
  2023-507342-84-00 5 2021-10-26 Bladder Cancer
• Pembrolizumab/placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer. Ended recruitment
  2023-506177-35-00 11 2021-10-23 Ovarian, fallopian tube, or primary peritoneal carcinoma.
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic … Ended recruitment
  2023-506256-25-00 5 2021-10-20 Active Psoriatic Arthritis
• EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER … Ended recruitment
  2023-506786-63-00 5 2021-09-30 Breast Cancer
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic … Ended recruitment
  2023-506752-24-00 5 2021-08-05 Locally recurrent inoperable or metastatic HR+/HER2- breast cancer, wh
• Hydrocorticose and vasopressin in post-resuscitation syndrome Ended recruitment
  2024-516373-77-00 5 2021-07-18 Adult cardiac arrest patients with sustained ROSC and hemodynamic fail
• A Study Evaluating the Efficacy and Safety of Crovalimab in Adult and Adolescent Patients with atypical Hemolytic Uremic Syndrome (aHUS) Ended recruitment
  2023-505089-27-00 5 2021-07-01 Atypical Hemolytic Uremic Syndrome (aHUS)
• Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive … Ended recruitment
  2023-505249-24-00 5 2021-05-27 HER2-positive metastatic breast cancer
• A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER … Ended recruitment
  2023-503995-26-00 5 2021-05-11 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer
• A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juven … Ended recruitment
  2023-507184-19-00 5 2021-02-22 Juvenile Psoriatic Arthritis  Enthesitis Related Arthritis
• Encorafenib in combination with Binimetinib in Patients with BRAFV600E mutant metastatic Lung Cancer Ended recruitment
  2024-515944-22-00 4 2021-01-19 BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
• A study comparing the efficacy and safety of osimertinib when given in combination with chemotherapy versus osimertinib alone in patients wi … Ended recruitment
  2023-508800-39-00 5 2020-09-29 Patients with locally-advanced or metastatic EGFRm (Ex19del and/or L85
• Capivasertib + Abiraterone as Treatment for Patients with Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency (CAP … Ended recruitment
  2023-504998-20-00 5 2020-09-18 Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN def
• Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab. Ended recruitment
  2023-510248-19-00 5 2020-01-21 Eosinophilic Granulomatosis with Polyangiitis (EGPA)
• Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive, … Ended recruitment
  2024-516847-23-00 4 2019-08-27 ER-positive and HER2-negative metastatic or locally advanced breast ca

Showing 193–216 of 273 trials